Skip to content
Log in
Sponsored AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI

Author

T. Taha

h-index 10 View on Semantic Scholar

We have 5 of 66 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

HoLEP Versus Mini-HoLEP: A Long-term Follow-up Prospective Randomized Controlled Trial

Take Home Message Mini–holmium laser enucleation of the prostate significantly reduces post–holmium laser enucleation of the prostate (HoLEP) urinary incontinence rates and improves recovery times compared with standard 26 Fr HoLEP. It also presents a better intraoperative profile and procedural efficiency while mainta...

Tomer Mendelson, O. S. Gildor, Ziv Savin et al. · 0 citations
Editorial Sep 2026

Challenges of Using Circulating Tumour DNA: Insights from Advanced Prostate Cancer.

Precision oncology relies on integrating tumour fraction, variant allele frequency, clonal haematopoiesis of indeterminate potential assessment, pathogenicity, and clinical context into next-generation sequencing interpretation, enabling biologically informed and clinically meaningful treatment decisions while reducing...

T. Taha, Ossian Longoria, J. de Bono · 0 citations
Review Open access Oct 2026

Durable Response to Immune Checkpoint Inhibition in Small Cell Carcinoma of the Bladder: A Case-Based Review of Immunotherapy and CNS Relapse

Background: Small cell carcinoma of the bladder (SCCB) is a rare, aggressive malignancy with no established standard of care for metastatic disease. The prognosis is dismal; median survival ranges from 12 to 20 months, and long-term survival is exceptional. Case Presentation: We present a 67-year-old man diagnosed in 2...

J. Baranseh, T. Taha, B. Talmor et al. · 0 citations
Review Open access Jul 2026

DLL3-Targeted Strategies in Advanced Prostate Cancer: Current Evidence and Future Perspectives

Delta-like ligand 3-directed therapies may reshape the management of DLL3-expressing prostate cancer if ongoing efforts to refine biomarkers improve patient enrichment and optimize trial design are successfully translated into clinical practice.

Giovanna Pecoraro, A. De Giorgi, G. Montelatici et al. · 0 citations
#explainable ai Sep 2026

Machine learning integrated explainable artificial intelligence in predicting toxicities of enfortumab vedotin in urothelial carcinoma: an exploratory study.

Preliminary, hypothesis-generating findings suggest ML may predict EV-related toxicities, but single train-test split, small event counts, and lack of external validation preclude clinical use.

K. Sridharan, Mattia Alberto Di Civita, G. Sivaramakrishnan et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.